CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
together works in treating patients with previously untreated chronic lymphocytic leukemia (CLL). Monoclonal antibodies, s...
Phase 2
Chicago, Illinois, United States and 1 other location
The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of t...
Phase 2
Evanston, Illinois, United States and 7 other locations
The purpose of this study is to evaluate the efficacy and safety of ibrutinib + venetoclax (I+V) and ibrutinib monotherapy regimens in which dosing o...
Phase 2
Hinsdale, Illinois, United States of America and 67 other locations
This study is designed to evaluate progression-free survival (PFS) endpoint for acalabrutinib versus (vs) ibrutinib in previously treated chronic...
Phase 3
Harvey, Illinois, United States and 130 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Dyer, Indiana, United States and 11 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Chicago, Illinois, United States and 79 other locations
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL)...
Phase 3
Chicago, Illinois, United States and 231 other locations
This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia...
Phase 1
Chicago, Illinois, United States and 11 other locations
ALLO-501A in adults with relapsed or refractory large B-cell lymphoma and assess the safety of ALLO-501A in adults with relapsed or refractory chronic...
Phase 1, Phase 2
Maywood, Illinois, United States and 38 other locations
To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...
Phase 3
Chicago, Illinois, United States and 178 other locations
Clinical trials
Research sites
Resources
Legal